Abstract
Endoscopic submucosal dissection (ESD) is an increasingly common technique for resection of early gastric cancers. Eight weeks proton pump inhibitor (PPI) treatment has been reported to heal patients with ESD induced artificial ulcer; however, anecdotally, not all patients are healed, particularly those with severe atrophic gastritis, for whom there is little data. We aimed to examine whether addition of the non-PPI mucosal healing agent, rebamipide after ESD improves healing rates, particularly in cases of severe atrophic gastritis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
